These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38356670)

  • 21. Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial.
    Kaye KS; Belley A; Barth P; Lahlou O; Knechtle P; Motta P; Velicitat P
    JAMA; 2022 Oct; 328(13):1304-1314. PubMed ID: 36194218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical use of beta-lactamase inhibitors in combination with extended-spectrum penicillins.
    Jones RN
    Am J Health Syst Pharm; 1995 Mar; 52(6 Suppl 2):S29-33. PubMed ID: 7606587
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.
    Kuck NA; Jacobus NV; Petersen PJ; Weiss WJ; Testa RT
    Antimicrob Agents Chemother; 1989 Nov; 33(11):1964-9. PubMed ID: 2558615
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.
    Bryson HM; Brogden RN
    Drugs; 1994 Mar; 47(3):506-35. PubMed ID: 7514977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of piperacillin/tazobactam versus other broad-spectrum antibiotics against nosocomial gram-negative pathogens isolated from burn patients.
    Mokaddas E; Rotimi VO; Sanyal SC
    J Chemother; 1998 Jun; 10(3):208-14. PubMed ID: 9669645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer.
    Cometta A; Zinner S; de Bock R; Calandra T; Gaya H; Klastersky J; Langenaeken J; Paesmans M; Viscoli C; Glauser MP
    Antimicrob Agents Chemother; 1995 Feb; 39(2):445-52. PubMed ID: 7726513
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections.
    Johnson DM; Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2002 May; 43(1):49-60. PubMed ID: 12052629
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microbiologic clearance following transition from standard infusion piperacillin-tazobactam to extended-infusion for persistent Gram-negative bacteremia and possible endocarditis: A case report and review of the literature.
    D'Agostino C; Rhodes NJ; Skoglund E; Roberts JA; Scheetz MH
    J Infect Chemother; 2015 Oct; 21(10):742-6. PubMed ID: 26143049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibiotic-induced black hairy tongue: two case reports and a review of the literature.
    Ren J; Zheng Y; Du H; Wang S; Liu L; Duan W; Zhang Z; Heng L; Yang Q
    J Int Med Res; 2020 Oct; 48(10):300060520961279. PubMed ID: 33044871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Piperacillin/tazobactam: a critical review of the evolving clinical literature.
    Sanders WE; Sanders CC
    Clin Infect Dis; 1996 Jan; 22(1):107-23. PubMed ID: 8824974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial.
    Alvarez-Lerma F; Insausti-Ordeñana J; Jordá-Marcos R; Maraví-Poma E; Torres-Martí A; Nava J; Martínez-Pellús A; Palomar M; Barcenilla F;
    Intensive Care Med; 2001 Mar; 27(3):493-502. PubMed ID: 11355117
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cefepime challenge after piperacillin/tazobactam-induced thrombocytopenia.
    Beaulieu C; Kurczewski L; Yajnik V
    J Thromb Thrombolysis; 2019 Jul; 48(1):167-170. PubMed ID: 30968302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A puerperal patient with agranulocytosis during tazobactam / piperacillin administration : A case report.
    Iwazawa H; Tanaka H; Tatsumichi T; Yamaguchi K; Takahashi K; Suzuki K; Motoki T; Kanenishi K; Kosaka S
    J Med Invest; 2021; 68(3.4):368-371. PubMed ID: 34759160
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study).
    Titov I; Wunderink RG; Roquilly A; Rodríguez Gonzalez D; David-Wang A; Boucher HW; Kaye KS; Losada MC; Du J; Tipping R; Rizk ML; Patel M; Brown ML; Young K; Kartsonis NA; Butterton JR; Paschke A; Chen LF
    Clin Infect Dis; 2021 Dec; 73(11):e4539-e4548. PubMed ID: 32785589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug Fever Induced by Piperacillin/Tazobactam in a Scoliosis Patient: A Case Report.
    Li Z; Shen J; Li Q; Chan MTV; Wu WKK
    Medicine (Baltimore); 2015 Nov; 94(46):e1875. PubMed ID: 26579799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imipenem-resistant Pseudomonas aeruginosa treated with piperacillin/tazobactam in a patient with severe pneumonia: a case report and related literature review.
    He L; He A; Qian Y
    Ann Palliat Med; 2021 Jan; 10(1):810-817. PubMed ID: 33545803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In-vitro activity of piperacillin/tazobactam relative to other antibiotics against blood culture isolates.
    Cormican M; Corbett-Feeney G; Kelly S; Hughes D; Flynn J; Jones RN
    Ir J Med Sci; 1998; 167(3):155-9. PubMed ID: 9780564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group.
    Eklund AE; Nord CE
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():79-85. PubMed ID: 8383657
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Initial empirical antimicrobial therapy with piperacillin/tazobactam in intra-abdominal infections due to perforation of the large intestine and rectum and in postoperative complications after resection of the large intestine and rectum].
    Vyhnánek F; Faltýn J; Lochmann O
    Rozhl Chir; 2002 Dec; 81(12):617-21. PubMed ID: 12666475
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative activity of piperacillin/tazobactam against 5625 isolates from hospitalised patients. Multicentre Study Group.
    Verbist L; Verhaegen J; Wouters C; Vandenhoven G
    J Antimicrob Chemother; 1996 Feb; 37(2):285-93. PubMed ID: 8707738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.